Form 4: Akero Therapeutics Director Seth Loring Harrison Receives Significant RSU Grant

Akero Therapeutics, Inc. Director Seth Loring Harrison was granted 9,398 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.

Summary

• Seth Loring Harrison, a Director of Akero Therapeutics, Inc. (AKRO), acquired 9,398 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 3, 2025, with a deemed acquisition price of $0 per RSU, typical for compensation grants.
• Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
• These RSUs are scheduled to vest in full on the earlier of June 3, 2026, or the date of the next annual meeting of the Company's stockholders, subject to Mr. Harrison's continued service on the Board.
• Following this transaction, Mr. Harrison directly beneficially owns 145,699 shares and indirectly owns 148,063 shares through Les Pommes, LLC.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally a positive signal as it aligns the director's interests with shareholder value and encourages long-term commitment. It's a standard compensation practice and not indicative of negative company performance.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is directly tied to the company's stock performance.
• The vesting schedule, contingent on continued service, encourages long-term commitment and retention of the director on the Board.

Future Outlook

This Form 4 filing is a disclosure of an insider equity transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. It reflects standard compensation practices for board directors, aligning their interests with long-term shareholder value. Such grants are a typical component of executive and director compensation packages in the biotechnology sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common compensation practice in the biotechnology and pharmaceutical industry, similar to how directors are compensated at companies like Gilead Sciences, Amgen, or Biogen.
• The vesting schedule tied to continued service is also standard, promoting long-term commitment and retention.
• The specific number of units granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Related Party Transactions

• Indirect beneficial ownership of 148,063 shares is held through Les Pommes, LLC, a family limited liability company for which the Reporting Person is the manager. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The granted RSUs are expected to vest on the earlier of June 3, 2026, or the next annual meeting of the Company's stockholders, subject to continued service.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership